secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001193125-22-046662
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma enters $20M SVB loan facility with tranche A of $10M available immediately
--------------------------------------------------------------------------------

- Tranche A of $10M funded at closing; two additional tranches up to $5M each contingent on CUE-101 data and equity proceeds.
- Interest rate: prime plus 2.25% (floor 5.5%); repayment begins June 2023 or Dec 2023 if tranche B advanced; maturity Dec 2025.
- Prepayment premium: 3% within 1yr, 2% 1-2yr, 1% after 2yr; final payment fee 5% of original principal.
- Secured by substantially all assets except IP (negative pledge); requires cash at SVB equal to lesser of all cash or 110% of obligations.
- Standard events of default; default triggers 3% rate increase and acceleration of all obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312522046662/0001193125-22-046662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312522046662/d302848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-046662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer